The global Long Acting Drug Delivery market size was valued at USD 1580.5 million in 2023 and is forecast to a readjusted size of USD 2321.5 million by 2030 with a CAGR of 5.6% during review period.
Long acting drug delivery systems involve slow absorption of a drug containing active pharmaceutical ingredients, which are released into the system over subsequent time. The role of long acting drug delivery systems is clinically and medically beneficial for the treatment of chronic diseases and chronic pain, as well as certain neurological disorders. Long acting drug delivery systems include injectables, implants, microarrays or micro needle patches and broadly neutralizing monoclonal antibodies. The demand of long acting drug delivery systems is largely based on their high efficiency and targeted method of drug delivery.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report includes an overview of the development of the Long Acting Drug Delivery industry chain, the market status of Hospital (Device, Parenteral Injections), Specialty Clinics (Device, Parenteral Injections), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Long Acting Drug Delivery.
Regionally, the report analyzes the Long Acting Drug Delivery markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Long Acting Drug Delivery market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Long Acting Drug Delivery market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Long Acting Drug Delivery industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Device, Parenteral Injections).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Long Acting Drug Delivery market.
Regional Analysis: The report involves examining the Long Acting Drug Delivery market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Long Acting Drug Delivery market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Long Acting Drug Delivery:
Company Analysis: Report covers individual Long Acting Drug Delivery players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Long Acting Drug Delivery This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Specialty Clinics).
Technology Analysis: Report covers specific technologies relevant to Long Acting Drug Delivery. It assesses the current state, advancements, and potential future developments in Long Acting Drug Delivery areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Long Acting Drug Delivery market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Long Acting Drug Delivery market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Device
Parenteral Injections
麻豆原创 segment by Application
Hospital
Specialty Clinics
Clinical Research Institutes
Others
麻豆原创 segment by players, this report covers
ViiV Healthcare
Halozyme Therapeutics
Lubrizol Life Science
Celanese Corporation
Kashiv BioSciences
4P Therapeutics
Ipsen
Midatech Pharma
Re-Vana Therapeutics
Creative Biolabs
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Long Acting Drug Delivery product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Long Acting Drug Delivery, with revenue, gross margin and global market share of Long Acting Drug Delivery from 2019 to 2024.
Chapter 3, the Long Acting Drug Delivery competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Long Acting Drug Delivery market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Long Acting Drug Delivery.
Chapter 13, to describe Long Acting Drug Delivery research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Long Acting Drug Delivery
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Long Acting Drug Delivery by Type
1.3.1 Overview: Global Long Acting Drug Delivery 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Long Acting Drug Delivery Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Device
1.3.4 Parenteral Injections
1.4 Global Long Acting Drug Delivery 麻豆原创 by Application
1.4.1 Overview: Global Long Acting Drug Delivery 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Specialty Clinics
1.4.4 Clinical Research Institutes
1.4.5 Others
1.5 Global Long Acting Drug Delivery 麻豆原创 Size & Forecast
1.6 Global Long Acting Drug Delivery 麻豆原创 Size and Forecast by Region
1.6.1 Global Long Acting Drug Delivery 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Long Acting Drug Delivery 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Long Acting Drug Delivery 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Long Acting Drug Delivery 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Long Acting Drug Delivery 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Long Acting Drug Delivery 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Long Acting Drug Delivery 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 ViiV Healthcare
2.1.1 ViiV Healthcare Details
2.1.2 ViiV Healthcare Major Business
2.1.3 ViiV Healthcare Long Acting Drug Delivery Product and Solutions
2.1.4 ViiV Healthcare Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 ViiV Healthcare Recent Developments and Future Plans
2.2 Halozyme Therapeutics
2.2.1 Halozyme Therapeutics Details
2.2.2 Halozyme Therapeutics Major Business
2.2.3 Halozyme Therapeutics Long Acting Drug Delivery Product and Solutions
2.2.4 Halozyme Therapeutics Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Halozyme Therapeutics Recent Developments and Future Plans
2.3 Lubrizol Life Science
2.3.1 Lubrizol Life Science Details
2.3.2 Lubrizol Life Science Major Business
2.3.3 Lubrizol Life Science Long Acting Drug Delivery Product and Solutions
2.3.4 Lubrizol Life Science Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Lubrizol Life Science Recent Developments and Future Plans
2.4 Celanese Corporation
2.4.1 Celanese Corporation Details
2.4.2 Celanese Corporation Major Business
2.4.3 Celanese Corporation Long Acting Drug Delivery Product and Solutions
2.4.4 Celanese Corporation Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Celanese Corporation Recent Developments and Future Plans
2.5 Kashiv BioSciences
2.5.1 Kashiv BioSciences Details
2.5.2 Kashiv BioSciences Major Business
2.5.3 Kashiv BioSciences Long Acting Drug Delivery Product and Solutions
2.5.4 Kashiv BioSciences Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Kashiv BioSciences Recent Developments and Future Plans
2.6 4P Therapeutics
2.6.1 4P Therapeutics Details
2.6.2 4P Therapeutics Major Business
2.6.3 4P Therapeutics Long Acting Drug Delivery Product and Solutions
2.6.4 4P Therapeutics Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 4P Therapeutics Recent Developments and Future Plans
2.7 Ipsen
2.7.1 Ipsen Details
2.7.2 Ipsen Major Business
2.7.3 Ipsen Long Acting Drug Delivery Product and Solutions
2.7.4 Ipsen Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Ipsen Recent Developments and Future Plans
2.8 Midatech Pharma
2.8.1 Midatech Pharma Details
2.8.2 Midatech Pharma Major Business
2.8.3 Midatech Pharma Long Acting Drug Delivery Product and Solutions
2.8.4 Midatech Pharma Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Midatech Pharma Recent Developments and Future Plans
2.9 Re-Vana Therapeutics
2.9.1 Re-Vana Therapeutics Details
2.9.2 Re-Vana Therapeutics Major Business
2.9.3 Re-Vana Therapeutics Long Acting Drug Delivery Product and Solutions
2.9.4 Re-Vana Therapeutics Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Re-Vana Therapeutics Recent Developments and Future Plans
2.10 Creative Biolabs
2.10.1 Creative Biolabs Details
2.10.2 Creative Biolabs Major Business
2.10.3 Creative Biolabs Long Acting Drug Delivery Product and Solutions
2.10.4 Creative Biolabs Long Acting Drug Delivery Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Creative Biolabs Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Long Acting Drug Delivery Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Long Acting Drug Delivery by Company Revenue
3.2.2 Top 3 Long Acting Drug Delivery Players 麻豆原创 Share in 2023
3.2.3 Top 6 Long Acting Drug Delivery Players 麻豆原创 Share in 2023
3.3 Long Acting Drug Delivery 麻豆原创: Overall Company Footprint Analysis
3.3.1 Long Acting Drug Delivery 麻豆原创: Region Footprint
3.3.2 Long Acting Drug Delivery 麻豆原创: Company Product Type Footprint
3.3.3 Long Acting Drug Delivery 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Long Acting Drug Delivery Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Long Acting Drug Delivery 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Long Acting Drug Delivery Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Long Acting Drug Delivery 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Long Acting Drug Delivery Consumption Value by Type (2019-2030)
6.2 North America Long Acting Drug Delivery Consumption Value by Application (2019-2030)
6.3 North America Long Acting Drug Delivery 麻豆原创 Size by Country
6.3.1 North America Long Acting Drug Delivery Consumption Value by Country (2019-2030)
6.3.2 United States Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Long Acting Drug Delivery Consumption Value by Type (2019-2030)
7.2 Europe Long Acting Drug Delivery Consumption Value by Application (2019-2030)
7.3 Europe Long Acting Drug Delivery 麻豆原创 Size by Country
7.3.1 Europe Long Acting Drug Delivery Consumption Value by Country (2019-2030)
7.3.2 Germany Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Long Acting Drug Delivery Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Long Acting Drug Delivery Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Long Acting Drug Delivery 麻豆原创 Size by Region
8.3.1 Asia-Pacific Long Acting Drug Delivery Consumption Value by Region (2019-2030)
8.3.2 China Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Long Acting Drug Delivery Consumption Value by Type (2019-2030)
9.2 South America Long Acting Drug Delivery Consumption Value by Application (2019-2030)
9.3 South America Long Acting Drug Delivery 麻豆原创 Size by Country
9.3.1 South America Long Acting Drug Delivery Consumption Value by Country (2019-2030)
9.3.2 Brazil Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Long Acting Drug Delivery Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Long Acting Drug Delivery Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Long Acting Drug Delivery 麻豆原创 Size by Country
10.3.1 Middle East & Africa Long Acting Drug Delivery Consumption Value by Country (2019-2030)
10.3.2 Turkey Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Long Acting Drug Delivery 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Long Acting Drug Delivery 麻豆原创 Drivers
11.2 Long Acting Drug Delivery 麻豆原创 Restraints
11.3 Long Acting Drug Delivery Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Long Acting Drug Delivery Industry Chain
12.2 Long Acting Drug Delivery Upstream Analysis
12.3 Long Acting Drug Delivery Midstream Analysis
12.4 Long Acting Drug Delivery Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
ViiV Healthcare
Halozyme Therapeutics
Lubrizol Life Science
Celanese Corporation
Kashiv BioSciences
4P Therapeutics
Ipsen
Midatech Pharma
Re-Vana Therapeutics
Creative Biolabs
听
听
*If Applicable.
